Rigel Pharmaceuticals, Inc.
General ticker "RIGL" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $430.0M (TTM average)
Rigel Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 48.5%.
Estimated limits based on current volatility of 3.6%: low 36.75$, high 39.51$
Factors to consider:
- Total employees count: 162 (+10.2%) as of 2024
- Top business risk factors: Market opportunity risks, Product development risks, Supply chain disruptions, Cybersecurity threats, Labor/talent shortage/retention
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [17.66$, 38.08$]
- 2025-12-31 to 2026-12-31 estimated range: [16.46$, 35.28$]
Financial Metrics affecting the RIGL estimates:
- Positive: with PPE of 18.0 at the end of fiscal year the price was neutral
- Positive: 7.54 < Operating profit margin, % of 13.49
- Positive: Inventory ratio change, % of -1.87 <= -0.76
- Positive: 6.63 < Operating cash flow per share per price, % of 10.60
- Negative: negative Industry operating cash flow (median)
- Negative: Shareholder equity ratio, % of 2.01 <= 19.35
- Positive: Interest expense per share per price, % of 2.67 <= 3.31
- Negative: negative Industry operating income (median)
- Positive: Return on assets ratio (scaled to [-100,100]) of 9.64 > 6.04
Short-term RIGL quotes
Long-term RIGL plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $120.24MM | $116.88MM | $179.28MM |
| Operating Expenses | $175.79MM | $137.37MM | $155.09MM |
| Operating Income | $-55.55MM | $-20.49MM | $24.19MM |
| Non-Operating Income | $-3.02MM | $-4.60MM | $-5.83MM |
| Interest Expense | $3.71MM | $6.87MM | $7.92MM |
| R&D Expense | $60.27MM | $24.52MM | $23.38MM |
| Income(Loss) | $-58.57MM | $-25.09MM | $18.37MM |
| Taxes | $0.00MM | $0.00MM | $0.88MM |
| Profit(Loss)* | $-58.57MM | $-25.09MM | $17.48MM |
| Stockholders Equity | $-13.62MM | $-28.64MM | $3.29MM |
| Inventory | $9.12MM | $5.52MM | $6.00MM |
| Assets | $134.28MM | $117.22MM | $163.98MM |
| Operating Cash Flow | $-73.76MM | $-5.74MM | $31.47MM |
| Capital expenditure | $0.45MM | $15.00MM | $0.40MM |
| Investing Cash Flow | $72.78MM | $-4.30MM | $4.13MM |
| Financing Cash Flow | $6.55MM | $18.37MM | $-11.64MM |
| Earnings Per Share** | $-3.40 | $-1.44 | $0.99 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.